Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
234.62 K
Value Traded
-
Short % Float
8.67%
-20.79%Week
-40.74%1 Month
-56.52%3 Month
-56.52%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.14 M
EPS (TTM)
-3.44
P/E Ratio
-
Ent. Value
3.56 M
Total Shares
7.59 M
Float Shares
7.52 M
Insiders
0.97%
Institutions
16.16%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CNSY Catalyst Timeline
Dated clinical, regulatory and corporate events for Cerenome, Inc. Common Stock
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cerenome, Inc. Common Stock
16Total events
4Upcoming
0Tier-1 (high impact)
2026 to 2027Coverage
Upcoming catalysts 2
Event history 7
▲Product LaunchPost-Market
Launch of multiple CNSide Breast Cancer Protein Expression Assays
breast cancer CNS metastasessource ↗
▲Product LaunchPost-Market
Launch of CSF Molecular Profile Test
central nervous system cancerssource ↗
▲Reimbursement / PricingCNSidePost-Market
CNSide contracted reimbursement coverage reaches approximately 158 million covered lives
leptomeningeal metastasessource ↗
●Management ChangeCorporate
Samantha Fowlkes appointed VP and Head of Commercial Sales, CNSide Diagnostics
▲Reimbursement / PricingCNSidePost-Market
CNSide secures in-network agreement with Blue Cross Blue Shield of Michigan
leptomeningeal metastasessource ↗
▲Product LaunchCNSidePost-Market
CNSide launched in early 2026
leptomeningeal metastases / CNS cancerssource ↗
Past FDA Catalysts and PDUFA Decisions
How CNSY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D22 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.0x
rNPV / MCap
Top 92%
Micro Cap(rank 605 of 658)
Percentile Rank
Cerenome, Inc. Common Stock faces pipeline headwinds (22/100), with $190M risk-adjusted pipeline value, led by 186RNL in Ependymoma (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 186RNL Small moleculeNCT07061626 | Ependymoma | Phase 1 | NOT YET_RECRUITING | 56 | Mar 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every CNSY program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Guse KyleDirector | Option | 921 1,843 held | $0.00 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CNSY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CNSY for Q2 2026. | ||||
CNSY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CNSY ranks across every disease it competes in
Competitive Position is a premium feature
See how CNSY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCNSY News
-CNSY
Sep 30, 2026Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Cerenome, Inc. reported a positive business update for CNSide Diagnostics, highlighting $1.55 million in gross billings for Q3 2026. The company is on track to expand its testing menu and expects to cover approximately 200 million lives by early 2027. A favorable CMS pricing decision for its TCE Test is anticipated to take effect in January 2027.
Read more →-CNSY
Sep 25, 2026▲ +6.4%on this newsshared move
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
Cerenome, Inc. announced a business update call for its CNSide Diagnostics platform on September 30, 2026. The call will cover recent commercial developments, including billing and market access improvements. CEO Marc H. Hedrick highlighted the progress made since the platform's launch in early 2026 and aims to inform stakeholders about future growth plans.
Read more →-CNSY
Sep 22, 2026▲ +6.8%on this newsshared move
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
Cerenome, through its subsidiary CNSide Diagnostics, has secured an in-network agreement with Blue Cross Blue Shield of Michigan, enhancing coverage for its CNSide® CSF Tumor Cell Enumeration assay. This agreement, effective September 1, 2026, brings the total covered lives to approximately 158 million. The move is part of Cerenome's strategy to improve patient access and support physician adoption of its diagnostic tests.
Read more →-CNSY
Sep 16, 2026Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
Cerenome, Inc. has appointed Samantha Fowlkes as Vice President and Head of Commercial Sales for CNSide Diagnostics. With over two decades of experience in oncology diagnostics, Fowlkes will lead the commercial expansion of the CNSide platform. Her appointment is seen as crucial for enhancing relationships within the oncology community and accelerating the adoption of CNSide's innovative diagnostic technologies.
Read more →-CNSY
Sep 10, 2026Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Cerenome, Inc. has announced a financing agreement with 3i, LP for up to $20 million, aimed at supporting the scale-up of its CNSide® cerebrospinal fluid assay platform. The initial funding has been received, with future tranches contingent on achieving specific milestones. This financing is expected to extend the company's cash runway into 2028.
Read more →-CNSY
Aug 20, 2026▼ -6%on this news
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
Cerenome presented key findings at the 2026 SNO/ASCO CNS Metastases Conference, highlighting the pharmacokinetics and safety of REYOBIQ in treating leptomeningeal metastases. The ongoing trials show promising safety signals and effective drug activity. Additionally, a cost-of-care analysis indicates that earlier detection and management could significantly reduce treatment costs for patients.
Read more →-CNSY
Aug 14, 2026▼ -13%on this newsshared move
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
Cerenome, Inc. reported its second quarter 2026 financial results, highlighting substantial progress in its CNS oncology platform and a successful rebranding from Plus Therapeutics. The company continues to enroll patients in multiple clinical trials for its lead therapeutic REYOBIQ, with no dose-limiting toxicities reported. However, the company experienced a significant increase in operating loss compared to the previous year.
Read more →-CNSY
Aug 13, 2026Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
Cerenome, through its subsidiary CNSide Diagnostics, has secured an in-network agreement with Health Care Service Corporation. This agreement marks a significant milestone, achieving the company's goal for commercial payer coverage by 2026. As a result, CNSide's coverage will now extend to over 150 million lives, enhancing access to its services.
Read more →-CNSY
Aug 6, 2026Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
Cerenome has chosen XiFin Empower RCM to manage revenue cycle and clearinghouse services for its CNSide platform. This strategic move aims to accommodate the anticipated billing volumes as the CNSide assay is scheduled to start billing in Q3 2026. The company is preparing for a backlog of tests and concurrent case billing.
Read more →-CNSY
Jul 31, 2026Cerenome Launches as an Integrated CNS Oncology Company
Cerenome, formerly Plus Therapeutics, has launched as an integrated company focusing on CNS oncology. The company aims to enhance the detection, treatment, and understanding of CNS cancers through precision diagnostics, targeted therapeutics, and artificial intelligence. This strategic rebranding signifies a commitment to innovation in the oncology field.
Read more →-CNSY
Jul 28, 2026Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
Plus Therapeutics, Inc. announced its participation in the 2026 SNO/ASCO CNS Metastases Conference, where it will present posters on its REYOBIQ™ clinical development program and CNSide® diagnostic platform. This event signifies the company's commitment to advancing research in central nervous system metastases. The presentations aim to enhance awareness of their innovative therapies.
Read more →-CNSY
Jul 21, 2026Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics has announced a regional coverage agreement with Medical Mutual for its CNSide® cerebrospinal fluid assay, effective July 1, 2026. This agreement aims to improve access to diagnostic services for patients with metastatic CNS cancer. The coverage is expected to enhance treatment options and patient outcomes.
Read more →-CNSY
Jul 16, 2026Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
Plus Therapeutics has partnered with Genomic Testing Cooperative to integrate next-generation sequencing into its CNSide® CSF assay platform. This collaboration is expected to yield hundreds of DNA and RNA biomarkers from a single cerebrospinal fluid specimen. The initiative aligns with the updated NCCN Guidelines® which now recognize CSF circulating tumor cells.
Read more →-CNSY
Jul 14, 2026Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Plus Therapeutics announced that the updated NCCN guidelines continue to endorse cerebrospinal fluid (CSF) analysis for diagnosing and managing leptomeningeal metastases. The guidelines recommend CSF cytology follow-ups every 4 to 8 weeks for patients undergoing intrathecal therapy, highlighting the importance of ongoing patient monitoring.
Read more →About Cerenome, Inc. Common Stock
Headquarters6420 LEVIT GREEN BOULEVARD, HOUSTON, TX, 77021
BIOPHARMAWATCH ELITE PLUS
Trade the next CNSY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime